Masitinib in Refractory Active Rheumatoid Arthritis

NCT01410695 · clinicaltrials.gov ↗

PHASE2,PHASE3

Phase

TERMINATED

Status

324

Enrollment

INDUSTRY

Sponsor class

Stopped Sponsor decision based on portfolio prioritization

Conditions

Rheumatoid Arthritis (RA)

Interventions

DRUG: masitinib 3 mg
DRUG: masitinib 6.0 mg
DRUG: methotrexate
DRUG: Placebo (methotrexate)
DRUG: Placebo (masitinib)

Sponsor

AB Science